Anti-MUC16/CA125 Monoclonal Antibody for WB, IHC-P, IP, ELISA - Q8WXI7

Core Product Specifications and Parameters

Biological Background: MUC16/CA125 Function and Localization

• Mucin-16 (MUC16), also known as CA125, is a large transmembrane glycoprotein that provides a protective, lubricating barrier against particles and infectious agents at mucosal surfaces.
• It localizes to the cell membrane and is also secreted into the extracellular space, where it can be detected as a soluble biomarker.
• MUC16 is expressed in corneal and conjunctival epithelia, and its overexpression in ovarian carcinomas and low malignant potential tumors makes it a critical ovarian cancer marker.
• UniProt annotations classify MUC16 as a glycoprotein with extensive repeat domains, a transmembrane helix, disulfide bonds, and phosphorylation sites, consistent with its structural and signaling roles.

Experimental Guidance and Technical Tips

• The immunogen corresponds to the extracellular C‑terminal region (amino acids 12660‑12923), enabling detection of both membrane‑bound and shed forms in ELISA and western blotting.
• For western blot, note that the full‑length protein is ~1500 kDa, but cleavage products or recombinant fragments may be smaller; consider including relevant positive controls from ovarian cancer cell lines.
• In immunohistochemistry (IHC‑P), optimize antigen retrieval conditions and validate with appropriate positive and negative tissue controls.
• For sandwich ELISA, pairing this detection antibody with a compatible capture antibody may enhance sensitivity; confirm performance in the intended sample matrix.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio offers a comprehensive portfolio of IVD raw materials, making it your ideal partner for ovarian cancer biomarker assay development. Beyond this anti‑MUC16/CA125 clone, we supply validated antibody pairs, antigen‑grade recombinant proteins, and bulk ancillary reagents to accelerate kit formulation. Our streamlined sourcing model covers rare‑target reagents and supports seamless scale‑up, helping you move efficiently from concept to clinic.